Allogeneic Transplantation for Patients with Poor-Risk Acute Myeloid Leukemia

AML patients with monosomal karyotype had a lower survival rate 4 years after allogeneic hematopoietic cell transplantation than those without this poor-risk marker.

The karyotype at the time of diagnosis of acute myeloid leukemia (AML) is among the strongest predictors of treatment outcome and survival. The monosomal karyotype (MK) — defined as two or more autosomal monosomies, such as del(5) or del(7), or a single monosomy plus other structural karyotypic changes — has been associated with an exceedingly poor outcome, with virtually no survivors after standard chemotherapy regimens. The only MK-positive AML patients who were alive >6 years after diagnosis were those who had received allogeneic hematopoietic cell transplantation (HCT) during remission (Blood 2010; 116:2224).

To further assess the efficacy of allogeneic HCT in MK-positive AML patients, investigators conducted a single-institution, retros…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee